Japanese practice of comprehensive treatment for peritoneal metastasis of gastric cancer
10.3760/cma.j.cn441530-20230706-00238
- VernacularTitle:胃癌腹膜转移综合治疗日本实践
- Author:
Yang LIU
1
;
Yonemura YUTAKA
;
Kitai TOSHIYUKI
;
Yan LI
Author Information
1. 岸和田德州会病院腹膜种植中心，日本大阪 596-0042
- Keywords:
Stomach neoplasms;
Peritoneal metastasis;
Comprehensive treatment
- From:
Chinese Journal of Gastrointestinal Surgery
2023;26(10):992-996
- CountryChina
- Language:Chinese
-
Abstract:
Patients with peritoneal metastasis (PM) from gastric cancer (GC) have a poor prognosis. Surgery or systemic treatment alone hardly improves the prognosis and overall survival (OS). A newly developed comprehensive treatment involving a combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used to treat patients with PM from GC. The Peritoneal Dissemination Center of Kishiwada Tokushukai Hospital in Japan has been committed to treating patients with PM from GC. Selected patients undergo laparoscopic hyperthermic intraperitoneal chemotherapy (LHIPEC), preoperative intraperitoneal (IP) chemotherapy, and systemic chemotherapy that includes intravenous and oral chemotherapy prior to surgery. CRS plus HIPEC is then performed to achieve complete cytoreduction. Postoperative IP chemotherapy or systemic chemotherapy is also administered to nearly all patients. The results demonstrate that comprehensive treatment, including neoadjuvant chemotherapy and CRS plus HIPEC, can significantly improve the prognosis and OS of selected patients with PM from GC.
